Anticoagulant action of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, in umbilical cord and adult plasma: an in vitro examination

详细信息    查看全文

• 作者：Koestenberger ; Martin ; Gallistl ; Siegfried ; Cvirn ; Gerhard ; Baier ; Katrin ; Leschnik ; Bettina ; et. al.
• 关键词：aPTT ; activated partial-thromboplastin time ; AT ; antithrombin ; CT₀ ; clotting time without melagatran ; CT_m ; concentrations of melagatran ; DTI ; direct thrombin inhibitor ; EDTA ; ethylenediaminetetra-acetic acid ; ETP ; endogenous thrombin
• 刊名：Thrombosis Research
• 出版年：2005
• 出版时间：2005
• 年：2005
• 卷：115
• 期：1-2
• 页码：135-142
• 全文大小：145 K

文摘

Introduction:This study was performed to compare the anticoagulant activity of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, in umbilical cord plasma with that in adult plasma. In contrast with the most frequently administered anticoagulants, the heparins, melagatran acts independently of antithrombin (AT). As a consequence, administration of melagatran is of special interest in neonates, who have physiologically low levels of AT. Materials and methods: Plasma samples were activated under high (as used in standard clotting assays) and low (more comparable with the physiological milieu) coagulant challenge. In the absence of melagatran, adult plasma clotted significantly faster than umbilical cord plasma under high coagulant challenge. Conversely, under low coagulant challenge, clotting of adult plasma was significantly delayed compared with umbilical cord plasma. For both high and low coagulant challenges, clotting times increased and prothrombin fragment 1.2 and thrombinaaaantithrombin (TAT) formation decreased with melagatran in a concentration-dependent fashion in umbilical cord and adult plasma. With increasing melagatran concentrations, the quotient between prothrombin fragment 1.2 and TAT formation increased in adult and umbilical cord plasma under both high and low coagulant challenges. Results and conclusions: Our in vitro results cannot be directly extrapolated to clinical efficacy, but assessing the degree of inhibition of thrombin generation may be a useful surrogate for selecting effective doses of ximelagatran for in vivo studies in neonates with thromboembolic complications.